Cargando…
免疫检查点抑制剂相关皮肤不良反应诊治建议
Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Dermatologic toxicities appear to be one of the most prevalent irAEs. The most common symptoms are maculopap...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817433/ https://www.ncbi.nlm.nih.gov/pubmed/31650946 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.06 |